about
Contemporary approaches for imaging skeletal metastasisProstate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesReverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models.Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcomeNon-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle.Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.Prostate kallikrein markers in diagnosis, risk stratification and prognosis.Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen aloneCabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responsesWhole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer.Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened PMale infertility and prostate cancer risk: a nested case-control studyLow expression of SHP-2 is associated with less favorable prostate cancer outcomesProspective study on metabolic factors and risk of prostate cancermiR-34c is downregulated in prostate cancer and exerts tumor suppressive functions
P50
Q26798170-D1C8A3F5-0C69-432D-923C-8D2DA2FAA8C6Q26865810-179FA00D-74A0-4ED3-BC80-14EC2CE9450FQ27310815-43CAADE9-3387-45CB-B967-5C5C9AF9852AQ28477590-6ABEB04D-2B27-4031-BA31-E731FF1A1585Q33841759-2654AB63-189A-46B5-BCC5-61EF2488968AQ34130128-1A83B29F-D1EF-4C95-8384-937E32213808Q35089983-BDC83B0E-04A9-47F7-83D7-BD82671A38D0Q35675446-445623BC-F69B-478A-B841-6FCF3C47C762Q35683035-8EF3D503-97FB-4FF2-BADB-ACC46585219EQ35718345-3C6B1A7F-F2B0-48D8-AFCB-097AB85010ABQ35755818-6BFFA9F1-D794-4BE0-834B-9BB670B64C29Q35956405-C12889C4-2EEF-487E-BF68-F4EB65BBDA05Q35964874-E98A6535-5B0D-4C5D-A57B-12BB810DCF45Q35985270-F80D5CD4-55B7-4E43-A2E7-7245E2DD6ECBQ36108572-FCFC98B7-A983-42F7-93D0-A1D27866F1C2Q36142693-E07A8CCD-B004-4D09-B76D-2CCCFD063AB5Q36326373-1974E95B-0BF6-4A59-B1CB-16BE0B1F17EFQ36849160-084718CF-9706-42DE-8544-B96F19105FEEQ37109209-8E3757F7-06E9-4BD5-BB6D-6908E88FF071Q37518609-82BA4891-A1E4-44E2-9158-CB8F615283C2Q37671113-0B7A2F02-F4F4-4EB6-879F-FB55175ADD0EQ38431148-891ED9C2-5473-4004-850D-D44B5C59DEBBQ38434213-CA778270-536E-4FCB-A4CD-44B4DAC26EB2Q38439594-F4872B6C-95A2-4F76-A0C3-F8F4912A3592Q57239006-1932300B-25D9-40FA-AF28-E3B9B9C6470BQ84354866-041AC62E-1EFF-4E6B-BF6F-914BB4B70E03Q85563932-B94DFA69-10CD-4B8F-A3F2-E63EB258E149Q95447067-7335BD00-1036-4843-AF66-F37C5997363AQ95780206-FB99BB51-AEAE-4AC0-B9D8-4A5207AB1EB0
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
David Ulmert
@en
David Ulmert
@nl
type
label
David Ulmert
@en
David Ulmert
@nl
prefLabel
David Ulmert
@en
David Ulmert
@nl
P31
P496
0000-0001-8156-7823